Rhône-Poulenc

About: Rhône-Poulenc is a based out in . It is known for research contribution in the topics: Alkyl & Catalysis. The organization has 8909 authors who have published 8934 publications receiving 182241 citations. The organization is also known as: Rhone-Poulenc.

Pyrrolo (3,4-b) pyrazine derivatives

Abstract: The new compounds of the formula: WHEREIN A is a phenyl, pyridyl, pyridazinyl or 2-, 3-or 4quinolyl radical optionally substituted by halogen, alkyl of 1 through 4 carbon atoms, alkoxy of 1 through 4 carbon atoms, cyano and nitro, and n is zero or 1, possess pharmacological properties, and are particularly active as tranquillisers and anti-convulsant agents.

4 Benzoyl isoxazole derivatives

Abstract: 4-Benzoyl isoxazole derivatives of the formula I: wherein: R represents alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted cycloalkyl, -CO₂R³,-COR⁵,cyano,nitro, -CONR³¹R⁴ or a halogen atom; R¹ represents :- hydrogen , alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl or optionally substituted cycloalkyl R² represents :- halogen, R⁵, -SR⁵, -SOR⁵, -SO₂R⁵, -SO₂NR³¹R⁴,-CO₂R³, -COR⁵, -CONR³¹R⁴, -CSNR³¹R⁴, -OR⁵, a nitro group, a cyano group, a group -O(CH₂) q -OR⁵ or alkyl substituted by OR⁵; R³, R³¹ and R⁴, which may be the same or different, each represents:- hydrogen, alkyl or haloalkyl; R⁵ represents alkyl or haloalkyl; n represents an integer from 1 to 5; and q represents an integer from 1 to 3; and agriculturally acceptable salts thereof and their use as herbicides is described.

New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing them

Abstract: Novel farnesyl transferase inhibitors of general formula (I), the preparation thereof and pharmaceutical compositions containing said inhibitors, are disclosed. In general formula (I), R1 is Y-S-A1 (where Y is a hydrogen atom, an amino acid residue, a fatty acid residue, an alkyl or alkoxycarbonyl radical or a radical R4-S- where R4 is a C1-4 alkyl radical optionally substituted by a phenyl radical or a radical of general formula (II), wherein A1, X, X1, Y1, R'1, R2, R'2 and R are as defined below, and A1 is a C1-4 alkylene radical optionally alpha-substituted in the >C(X1)(Y1) grouping by an amino or alkylamino, dialkylamino, alkanoylamino or alkoxycarbonylamino radical); X1 and Y1 are each a hydrogen atom or, taken together with the carbon atom to which they are attached, form a >C=O grouping; R'1 is hydrogen or a C1-6 alkyl radical; X is an oxygen or sulphur atom; R2 is a C1-6 alkyl, alkenyl or alkynyl radical optionally substituted by hydroxy, alkoxy, mercapto, alkylthio, alkylsulphinyl or alkylsulphonyl, with the proviso that when R2 is an alkyl radical substituted by a hydroxy radical, R2 may form a lactone with the alpha -carboxy radical; and R'2 is hydrogen or a C1-6 alkyl radical; and R is a hydrogen atom or an optionally substituted alkyl radical or an optionally substituted phenyl radical, with the proviso that radical (a) is in the 3 or 4 position of the naphthyl ring. The novel products have anticancer properties.

Analgesia Produced by Stimulation of the Periaqueductal Gray Matter: True Antinoceptive Effects Versus Stress Effects

Abstract: Since Reynold’s initial report years ago (1969) revealed that during and after periaqueductal gray matter (PAG) stimulation rats could support severe, painful interventions such as laparotomies, the “stimulation produced analgesia phenomenon” (SPA) has been extensively studied in the rat, cat and monkey (see reviews in Liebeskind et al., 1976; Mayer and Price, 1976; Basbaum and Fields, 1978; Mayer, 1979; Besson et al., 1981; Basbaum and Fields, 1984; Oliveras and Besson, 1988). Furthermore, SPA from central gray (anatomically including the caudal periventricular hypothalamic region and the PAG) has been used to relieve severe intractable pain in human patients (Adams, 1976; Gybels et al., 1976; Hosobuchi et al., 1977; 1979; Richardson and Akil, 1977a,b). However, after an initial rush of enthusiasm by neurosurgical teams involved in this pain treatment, the use of central gray deep brain stimulation became controversial (Gybels et al., 1976; Meyerson, 1988). These controversies are justifiable in light of certain behavioral observations: the PAG and the central gray are complex regions involved in diverse functions and states including not only analgesia but also “intense emotion” (very unpleasant to intolerable sensations) when electrically stimulated in both human beings and animals.

Moulding compositions comprised of semirigid, fatty acid copolyamides, elastomers and optionally conventional polyamides

Abstract: Polyamide-based molding compositions having enhanced flexibility and resilience, especially at low temperatures, are prepared from (1) semirigid copolyamides prepared from fatty acid dimers, (2) elastomers containing moieties compatible or reactive with such copolyamides (1) and comprising olefinic copolymers bearing carboxyl and/or carboxylate groups, copolyester-amides, polyurethanes, organopolysiloxane and polyurethane block copolymers, and copolymers produced from a latex which comprises suitable functional groups, and, optionally, (3) conventional polyamides.